On October 20, Oracle and AstraZeneca announced a non-binding agreement to explore the use of AI and real-world data to identify patients eligible for clinical trials, accelerate medical evidence generation, and integrate findings into routine care. The companies will combine AstraZeneca's research expertise with Oracle's data, cloud, AI, and clinical workflow technologies, initially exploring applications in oncology, cardiovascular, renal and metabolic diseases, and plan to establish joint governance and evaluation metrics.
On October 15, 2026, AstraZeneca announced a strategic drug discovery collaboration and license agreement with AI drug discovery company insitro. insitro will use its Virtual Human platform to identify causal disease biology in MASH and cardiomyopathy and advance AstraZeneca-nominated targets to development candidate stage. AstraZeneca will pay $40 million upfront, up to approximately $1.46 billion in milestones, with total potential value of about $1.5 billion plus tiered royalties on global sales.